American journal of therapeutics最新文献

{"title":"Toripalimab-Associated Arthritis and Peripheral Neuropathy.","authors":"Qingru Liu, Jiao Xue, Wenjuan Ouyang, Ju Sheng, Leiyan He","doi":"10.1097/MJT.0000000000001846","DOIUrl":"10.1097/MJT.0000000000001846","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":"e341-e345"},"PeriodicalIF":2.9,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143952215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Superimposed Linear Psoriasis: Which Biologic Therapy to Choose?","authors":"Jian-Feng Hu, Ze-Hu Liu","doi":"10.1097/MJT.0000000000001858","DOIUrl":"10.1097/MJT.0000000000001858","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":"e356-e357"},"PeriodicalIF":2.9,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143972974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Profiles and Invasive Management of Patients With High-Risk Non-ST Elevation Acute Coronary Syndromes in Two University Hospitals From Romania and Germany.","authors":"Alexandru-George Cotoban, Amir A Mahabadi, Tienush Rassaf, Dragoș Vinereanu, Fadi Al-Rashid","doi":"10.1097/MJT.0000000000001864","DOIUrl":"https://doi.org/10.1097/MJT.0000000000001864","url":null,"abstract":"<p><strong>Background: </strong>Regional differences in cardiovascular disease (CVD), prevalence, and outcomes in the European population have been reported. Although current European Society of Cardiology guidelines recommend invasive coronary angiography (ICA) <24 hours from diagnosis in high-risk non-ST elevation acute coronary syndromes (NSTE-ACS), overall management remains heterogenous across Europe.</p><p><strong>Study question: </strong>What are the differences regarding profiles of patients with high-risk NSTE-ACS and factors associated with timing of ICA in 2 university hospitals from 2 European countries with different prevalence of CVD and different income (University and Emergency Hospital, Bucharest, Romania [RO] and University Hospital, Essen, Germany [GER])?</p><p><strong>Study design: </strong>Retrospective, observational, all-comers.</p><p><strong>Measures and outcomes: </strong>All consecutive invasively managed patients with high-risk NSTE-ACS in 2022 were retrospectively identified and analyzed regarding clinical profiles and factors associated with ICA timing in relation to the 24-hour European Society of Cardiology recommended interval.</p><p><strong>Results: </strong>A total of 587 patients were included: 301 from RO and 286 from GER. RO patients were younger (64.6 vs. 70.6 years, P < 0.001), with higher rates of obesity (P = 0.013), hypertension (P = 0.001), dyslipidemia (P < 0.001), diabetes (P < 0.001), and active smoking (P = 0.019), whereas GER patients had higher rates of previous myocardial revascularization (P < 0.001), chronic respiratory disease (P < 0.001), sleep apnea (P < 0.001), thyroid disorders (P < 0.001), and neoplasia (P = 0.036). About 68.1% patients from RO versus 74.8% from GER underwent ICA <24 hours (P = 0.006). Transfers and admission during cathlab on-hours in RO, diagnosis of myocardial infarction, and typical angina in GER were associated with ICA <24 hours (all P < 0.05).</p><p><strong>Conclusions: </strong>High-risk NSTE-ACS patient profiles mirrored overall regional CVD patterns. Compared to the German hospital, patients in the Romanian hospital had a worse CVD risk factor profile at a younger age, lower previous myocardial revascularization, and potentially underdiagnosed comorbidities. Health care system organization and hospital logistics largely influenced ICA timing in the Romanian hospital, opposite mainly patient characteristics in the German hospital.</p>","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":"32 3","pages":"e234-e241"},"PeriodicalIF":2.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143952693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Oral Gonadotropin-Releasing Hormone Antagonist, Relugolix, in Endometriosis: A Meta-Analysis of Randomized Clinical Trials.","authors":"Milene Vitória Sampaio Sobral, João Pedro Pereira Dos Santos, Tania Aparecida Alves Vilela, Rafaela da Cunha Pirolla, Fernando Augusto Barreiros, Marina Ayabe Gomes de Moraes","doi":"10.1097/MJT.0000000000001842","DOIUrl":"https://doi.org/10.1097/MJT.0000000000001842","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":"32 3","pages":"e309-e312"},"PeriodicalIF":2.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143958284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of Immunogenicity and Loss of Response to ANTI-TNFα Therapy in Crohn Disease-A Systematic Review.","authors":"Simona Grad, Radu A Farcas, Dan L Dumitrascu, Teodora Surdea-Blaga, Abdulrahman Ismaiel, Stefan Popa","doi":"10.1097/MJT.0000000000001867","DOIUrl":"https://doi.org/10.1097/MJT.0000000000001867","url":null,"abstract":"<p><strong>Background: </strong>As the use of anti-tumor necrosis factor-α (TNFα) therapies in Crohn disease (CD) is spread, the loss-of-response (LOR) to it is increasingly encountered. Discovering a pathological pathway and biomarkers that can predict LOR would assist in the management of patients with CD. In this article, we provide a comprehensive systematic review of studies assessing predictors of immunogenicity and loss-of-response to anti-TNFα drugs in patients with CD.</p><p><strong>Data sources: </strong>We performed a systematic review of PubMed to identify citations pertaining to predictors of immunogenicity and loss-of-response to anti-TNFα drugs in patients with CD through April 27, 2024, using a predefined string of keywords. Data extraction and quality assessment were performed independently by 2 reviewers.</p><p><strong>Results: </strong>A total of 18 eligible studies were included in the review. Four major groups of studies were identified: genetic factors, factors linked with colonic inflammation, serum and anthropological markers, and prevention of LOR. Promising predictors of LOR to infliximab or adalimumab include the carriage of HLA-DQA1*05, visceral adiposity, intestinal abundant presence of CD96, IL-17, and IL-23. Substantial heterogeneity was observed, and none of the markers had undergone formal validation. Specific limitations to acceptance of these factors included failure to use a standardized definition of LOR to anti-TNFα treatment, lack of specificity, and insufficient relevance to the pathogenesis of LOR.</p><p><strong>Conclusions: </strong>This review underlines the lack of well-defined studies and controlled trials investigating predictors of LOR to anti-TNFα therapies in CD. A research priority is the development of reliable and accurate biomarkers that can shed light on the pathogenesis of the implied LOR. These biomarkers, along with genetic factors, have the potential to enhance clinical management by aiding in patient stratification and monitoring.</p>","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":"32 3","pages":"e262-e268"},"PeriodicalIF":2.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144060930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fruquintinib for Adult Patients With Metastatic Colorectal Cancer.","authors":"Daniel Do, Celeste Dedic, Vanesa Pinderi, Maryann Cooper, Daniel Ciurescu, Lorena Dima","doi":"10.1097/MJT.0000000000001962","DOIUrl":"10.1097/MJT.0000000000001962","url":null,"abstract":"<p><strong>Background: </strong>Metastatic colorectal cancer (mCRC) represents a major clinical challenge, particularly for refractory patients who have exhausted standard treatments. Fruquintinib is an oral vascular endothelial growth factor receptor (VEGFR) inhibitor that has been approved by FDA for adult patients with mCRC who received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, vascular endothelial growth factor (VEGF) inhibitor therapy, and an epidermal growth factor receptor targeted therapy if RAS wild type.</p><p><strong>Areas of uncertainty: </strong>Despite advances in mCRC treatment, patients who progress after standard therapies face limited options. The efficacy of treatments tends to diminish and side effects can be intolerable. There is a need for therapies that can extend survival without worsening quality of life.</p><p><strong>Data sources: </strong>In the pivotal FRESCO-2 phase 3 trial, 691 patients with heavily pretreated mCRC were studied. Fruquintinib was found to significantly improve survival times, with a median overall survival (OS) of 7.4 months compared with 4.8 months with a placebo. Progression-free survival (PFS) also showed significant improvement with fruquintinib of 3.7 months versus 1.8 months in the placebo group. This was the first trial to show that an oral VEGFR inhibitor can be effective in refractory patients.</p><p><strong>Therapeutic advance: </strong>Fruquintinib represents a new treatment option for patients with mCRC who have limited therapeutic options. Fruquintinib has demonstrated statistically significant improvements in OS and PFS, in heavily pretreated patients. The FRESCO-2 trial demonstrated its efficacy, even in patients previously treated with trifluridine-tipiracil or regorafenib, showing a 34% reduction in OS and improved PFS.</p><p><strong>Conclusions: </strong>Fruquintinib, approved by FDA for heavily pretreated patients with mCRC, addresses an unmet need in this population. Future research should focus on optimizing its integration into treatment plans and identifying biomarkers for personalized therapy.</p>","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":"32 3","pages":"e278-e283"},"PeriodicalIF":2.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143962336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endoscopy Sedation Challenges in Patients With Hepatic Encephalopathy: A Focused Review on Propofol and Selective Use of Benzodiazepines.","authors":"Miruna V Moraru, Sandica Bucurica, Benjamin N A Proske, Smaranda Stoleru, Aurelian Zugravu, Oana A Coman, Ion Fulga","doi":"10.1097/MJT.0000000000001926","DOIUrl":"https://doi.org/10.1097/MJT.0000000000001926","url":null,"abstract":"<p><strong>Background: </strong>Hepatic encephalopathy (HE) presents a significant challenge in gastrointestinal endoscopy sedation due to impaired liver function, which alters drug metabolism and increases the risk of adverse effects. In the absence of clear guidelines and specific biomarkers for diagnosis and assessment of HE, there is insufficient evidence to formulate standardized protocols for management, diagnosis, and sedation during endoscopy.</p><p><strong>Areas of uncertainty: </strong>Rigid protocols for sedation are difficult to implement due to wide variation in patient age, comorbidities, and disease severity, which creates a \"gray zone.\" This leaves decisions heavily reliant on the clinician's preference or experience, patient characteristics, and institutional protocols. This review highlights the strengths and limitations of propofol, midazolam, and remimazolam in efforts to improve sedation strategies for endoscopic procedures in patients with HE.</p><p><strong>Data sources: </strong>A review was conducted using PubMed and Scopus databases, keeping in view recent publications. Only primary research studies were considered for this review. Inclusion was based on the relevance of patient side effects, sedation outcomes, and safety profiles, with a particular focus on gastrointestinal endoscopy procedures and their implications in HE.</p><p><strong>Results: </strong>Propofol remains preferred in patients with HE, demonstrating manageable cardiovascular and respiratory events without worsening encephalopathy. However, its safety requires careful consideration in this high-risk population. The combination of propofol with adjuncts, such as esketamine, has shown potential in mitigating adverse effects and optimizing sedation protocols in challenging cases. Midazolam, though historically used, is not recommended in HE due to exacerbation of encephalopathy and unfavorable safety profiles. While remimazolam shows promise, no evidence in HE populations precludes definitive conclusions about its efficacy and safety.</p><p><strong>Conclusions: </strong>Future research should focus on optimizing sedation protocols according to the needs of HE patients, including tools for risk stratification and guidelines considering individual patient profiles. Furthermore, studies must be performed to evaluate remimazolam's outcomes and safety profiles, both as a standalone sedative and in combination with other agents.</p>","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":"32 3","pages":"e247-e255"},"PeriodicalIF":2.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143958699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Attitudes and Knowledge of Medical Students in South of Israel Toward Medical Cannabis.","authors":"Richard Isralowitz, Patricia A Findley, Alexander Reznik","doi":"10.1097/MJT.0000000000001821","DOIUrl":"https://doi.org/10.1097/MJT.0000000000001821","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":"32 3","pages":"e301-e303"},"PeriodicalIF":2.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143962309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of a Combination Regimen of Jiawei Dachengqi Decoction and Shutaiqing on Intestinal Cleanness and Polyp Detection Rate.","authors":"Xiuqin Fan, Weiwei Wang, Jiayan Shen, Lulu Xia, Yunjie Qi, Hongshi Wang","doi":"10.1097/MJT.0000000000001915","DOIUrl":"https://doi.org/10.1097/MJT.0000000000001915","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":"32 3","pages":"e287-e291"},"PeriodicalIF":2.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143968523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dupilumab in the Treatment of Severe Atopic Dermatitis With Ocular Complications.","authors":"Jiping Xia, Yan Yu, Chengzhong Zhang","doi":"10.1097/MJT.0000000000001839","DOIUrl":"https://doi.org/10.1097/MJT.0000000000001839","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":"32 3","pages":"e307-e308"},"PeriodicalIF":2.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143965322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}